Phenotypes associated with this allele

• Allele Symbol: Ptprc^a
• Allele Name: a variant
• Allele ID: MGI:4819849
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Dhx9^Tn(pb-Act-RFP)1.071225026-HRAZhu/Dhx9^+ Igs12^tm1Zhu/Igs12^tm1Zhu Ptprc^a/Ptprc^b Tg(Lck-cre)#Zhu/0	involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ * SJL/J	MGI:5557973
cx2	Ncr1^m1J/Ncr1^m1J Pepc^b/Pepc^b Ptprc^a/Ptprc^a	B6.SJL-Ptprc^a Pepc^b/BoyJ	MGI:6140019

Genotype
MGI:5557973

cn1

• Allelic Composition: Dhx9^{Tn(pb-Act-RFP)1.071225026-HRAZhu}/Dhx9⁺; Igs12^tm1Zhu/Igs12^tm1Zhu; Ptprc^a/Ptprc^b; Tg(Lck-cre)#Zhu/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ * SJL/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal T cell differentiation ( J:207361 )

• stage-specific alterations in T cell maturation determined by the ratio of Ptprc^a to Ptprc^b expressing cells

hematopoietic system

abnormal T cell differentiation ( J:207361 )

• stage-specific alterations in T cell maturation determined by the ratio of Ptprc^a to Ptprc^b expressing cells

Genotype
MGI:6140019

cx2

• Allelic Composition: Ncr1^m1J/Ncr1^m1J; Pepc^b/Pepc^b; Ptprc^a/Ptprc^a
• Genetic Background: B6.SJL-Ptprc^a Pepc^b/BoyJ

hematopoietic system

abnormal NK cell physiology ( J:257226 )

• although lytic activity of NK cells is normal, fewer granzyme B positive NK cells are found after treatment with interleukin 15

• there is an increase in interferon gamma positive NK cells compared with controls after treatment with interleukin 12 plus 18, or anti-NK1.1 antibodies, and there is a significant increase in interferon gamma secretion by NK cells treated with anti-Ly49H antibodies for 6 hours

immune system

abnormal NK cell physiology ( J:257226 )

• although lytic activity of NK cells is normal, fewer granzyme B positive NK cells are found after treatment with interleukin 15

• there is an increase in interferon gamma positive NK cells compared with controls after treatment with interleukin 12 plus 18, or anti-NK1.1 antibodies, and there is a significant increase in interferon gamma secretion by NK cells treated with anti-Ly49H antibodies for 6 hours

abnormal interferon level ( J:257226 )

• increased NK cell interferon production in both liver and spleen after murine cytomegalovirus infection

abnormal susceptibility to infection induced morbidity/mortality ( J:257226 )

• although there is no difference in susceptibility to C rodentium bacterial infection, the Ncr1 point mutation causes altered response to viral infection

decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality ( J:257226 )

• increased survival after influenza A infection compared with controls

increased susceptibility to Herpesvirales infection induced morbidity/mortality ( J:257226 )

• Increased resistance to murine cytomegalovirus Smith strain compared with controls

homeostasis/metabolism

abnormal interferon level ( J:257226 )

• increased NK cell interferon production in both liver and spleen after murine cytomegalovirus infection

mortality/aging

abnormal susceptibility to infection induced morbidity/mortality ( J:257226 )

• although there is no difference in susceptibility to C rodentium bacterial infection, the Ncr1 point mutation causes altered response to viral infection

decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality ( J:257226 )

• increased survival after influenza A infection compared with controls

increased susceptibility to Herpesvirales infection induced morbidity/mortality ( J:257226 )

• Increased resistance to murine cytomegalovirus Smith strain compared with controls